Related Experiment Video
Updated: Aug 14, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Inhibitors of histone deacetylases as anti-inflammatory drugs
1University of Colorado Health Sciences Center, Denver 80262, USA. cdinare333@aol.com
Abstract:
This review addresses the issue of histone deacetylase (HDAC) inhibitors as developed for the treatment of cancer and for the investigation of the inhibition of inflammation. The review focuses on both in vitro and in vivo models of inflammation and autoimmunity. Of particular interest is the inhibition of pro-inflammatory cytokines. Although the reduction in cytokines appears paradoxical at first, upon examination, some genes that are anti-inflammatory are upregulated by inhibition of HDAC. Whether skin diseases will be affected by inhibitors of HDAC remains to be tested.
Insights
Histone deacetylase (HDAC) inhibitors show promise for treating cancer and inflammation by reducing pro-inflammatory cytokines. Some anti-inflammatory genes are upregulated by HDAC inhibition, suggesting broader therapeutic potential.
Area of Science:
- Pharmacology
- Immunology
- Molecular Biology
Background:
- Histone deacetylase (HDAC) inhibitors are investigated for cancer therapy.
- HDAC inhibitors also show potential in modulating inflammatory and autoimmune diseases.
- The precise mechanisms underlying their anti-inflammatory effects require further elucidation.
Purpose of the Study:
- To review the role of HDAC inhibitors in cancer treatment.
- To explore the application of HDAC inhibitors in managing inflammation and autoimmunity.
- To examine the impact of HDAC inhibition on pro-inflammatory cytokine production.
Main Methods:
- Review of in vitro studies on inflammation models.
- Analysis of in vivo studies in inflammation and autoimmunity.
- Examination of gene expression changes related to HDAC inhibition.
Main Results:
- HDAC inhibitors demonstrate efficacy in preclinical models of inflammation.
- Inhibition of pro-inflammatory cytokines is a key observed effect.
- Upregulation of anti-inflammatory genes by HDAC inhibition was noted, offering a potential explanation for therapeutic benefits.
Conclusions:
- HDAC inhibitors represent a promising therapeutic strategy for inflammatory conditions.
- Further research is needed to understand the full potential of HDAC inhibitors in treating inflammatory and autoimmune diseases.
- The effect of HDAC inhibitors on skin diseases warrants future investigation.
More Related Videos
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
09:20Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inhibitors of Viral Protein Synthesis
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...